Screening decreases prostate cancer death: First analysis of the 1988 Quebec Prospective Randomized Controlled Trial

Authors

  • Fernand Labrie,

    Corresponding author
    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    • Department of Medicine, Laboratory of Molecular Endocrinology, CHUL Research Center, 2705 Laurier Boulevard, Quebec, G1V 4G2, Canada
    Search for more papers by this author
  • Bernard Candas,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • André Dupont,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Lionel Cusan,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Jose-Luis Gomez,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Raul E. Suburu,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Pierre Diamond,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Jacques Lévesque,

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author
  • Alain Belanger

    1. Prostate Cancer Clinical Research Unit, Departments of Medicine and Radiology and Laboratory of Molecular Endocrinology, Laval University Medical Research Center (CHUL), Québec, Canada
    Search for more papers by this author

  • Dr. André Dupont is deceased.

Abstract

BACKGROUND

The 46,193 men aged 45 to 80 years registered in the electoral roll of Quebec City and its Metropolitan area were randomized in November 1988 between screening and no screening in a study aimed of assessing the impact of prostate cancer screening on cause-specific death.

METHODS

At first visit, screening included measurement of serum prostatic specific antigen (PSA) using 3.0 ng/ml as upper limit of normal and a digital rectal examination (DRE). Transrectal echography of the prostate (TRUS) was performed only if PSA and/or DRE was abnormal and biopsy was then done, only if PSA was above the predicted PSA value. At follow-up visits, PSA alone was used as prescreening.

RESULTS

137 deaths due to prostate cancer occurred between 1989 and 1996, inclusively, in the 38,056 unscreened men while only 5 deaths were observed among the 8,137 screened individuals. The prostate cancer death rates during the eight-year period were 48.7 and 15 per 100,000 man-years in the unscreened and screened groups, respectively, for a 3.25 odds ratio in favor of screening and early treatment (P < 0.01).

CONCLUSIONS

If PSA screening is started at the age of 50 years (or 45 years in the higher risk population), annual or biannual PSA alone is highly efficient to identify the men who are at high risk of having prostate cancer. Coupled with treatment of localized disease, this approach demonstrates, for the first time, that early diagnosis and treatment permits a dramatic decrease in deaths from prostate cancer. Prostate 38:83–91, 1999. © 1999 Wiley-Liss, Inc.

Ancillary